GSK’s $750 Mil. DOJ Settlement: When GMP Violations Equal Healthcare Fraud
“The Pink Sheet”
November 1, 2010
After the US Government settled a ground-breaking qui tam action, brought by a very courageous whistleblower involving manufacturing issues at a pharmaceutical plant, the esteemed industry trade publication The Pink Sheet turned to Nolan Auerbach partner Ken Nolan for expert insights. “In this particular case, if you read the facts, they are extreme,” explained Nolan. “And the whistleblower was the most well-positioned whistleblower for this type of case, so it was the perfect storm.”